by 
The Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 21.42 Bn in 2023 and is expected to exhibit a CAGR of 3.6% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Disease-modifying antirheumatic drugs (DMARDs) help reduce pain, stiffness, and swelling caused by rheumatoid arthritis. DMARDs slow down or stop damage to joints. Common DMARDs include methotrexate, hydroxychloroquine, and leflunomide. Biologics are a class of DMARDs that work by targeting specific molecules involved in the immune system. Popular biologics for rheumatoid arthritis include TNF inhibitors like Humira and Enbrel as well as anti-IL6 drugs. They are usually only prescribed for people with more severe rheumatoid arthritis.
Market Dynamics:
One of the major drivers for the Disease-Modifying Antirheumatic Drug (DMARD) market growth is the rising prevalence of rheumatoid arthritis. According to the Arthritis Foundation, around 54 million adults and 300,000 children suffer from rheumatoid arthritis in the U.S. Growing geriatric population worldwide which is more susceptible to rheumatoid arthritis would also fuel the market growth. Another driver is the increasing adoption of targeted biologics in the treatment of moderate to severe rheumatoid arthritis cases. Biologics have demonstrated better efficacy and fewer side effects compared to conventional DMARDs. With better efficacy, biologics are prescribed more often for rheumatoid arthritis patients which drives the overall DMARD market.
Segment Analysis
The Disease-Modifying Antirheumatic Drug (DMARD) market can be segmented into conventional synthetic DMARDs and biological DMARDs. The biological DMARDs segment currently dominates the market due to fewer side effects and higher efficacy compared to conventional synthetic DMARDs. Biological DMARDs are beneficial in the treatment of various chronic inflammatory conditions like rheumatoid arthritis and reduce symptoms more effectively.
PEST Analysis
Political: Government regulations promote the development and approval of innovative DMARDs to treat rheumatoid arthritis and other autoimmune disorders effectively. Economic: Rising healthcare expenditure and growing disposable income in developing nations boost the Disease-Modifying Antirheumatic Drug market size. Social: Increasing public awareness about arthritis treatment and management aids the demand for DMARDs. Technological: Advancements in biologics and personalized medicine allow development of targeted DMARDs with fewer side effects.
Key Takeaways
The global Disease-Modifying Antirheumatic Drug (DMARD) market is expected to witness high growth, exhibiting CAGR of 3.6% over the forecast period, due to increasing prevalence of arthritis disorders globally. The Asia Pacific region is projected to witness the fastest growth in the DMARD market during the analysis period owing to rapidly increasing healthcare expenditure, growing elderly population, and rising awareness about arthritis treatment.
Key players operating in the Disease-Modifying Antirheumatic Drug (DMARD) market are Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc. Major players are focusing on developing innovative targeted biologics with enhanced efficacy and fewer side effects to gain a competitive edge in the market.
Regional analysis: The North American region currently dominates the global DMARD market and is expected to retain its dominance over the forecast period owing to high healthcare spending and growing disposable income. Europe represents the second largest market globally for DMARDs. However, the Asia Pacific region is projected to register the highest growth rate during the analysis period. Factors such as rapidly developing healthcare infrastructure, increasing geriatric population, and rising prevalence of arthritis disorders drive the growth of the DMARD market in Asia Pacific.
